BioMarin Pharma (BMRN) Misses Q4 EPS Views

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. SPY
10. SNDX

Go back to BioMarin Pharma (BMRN) Misses Q4 EPS Views

BioMarin (BMRN) Reiterates Profitability in 2017 - Piper Jaffray

February 26, 2016 9:46 AM EST

Piper Jaffray analyst, Joshua Schimmer, sees numerous catalysts for BioMarin (NASDAQ: BMRN) as the company marches toward profitability. No change to Overweight rating but the PT is revised down to $107.

BMRN has spent years with aggressive opex and burning cash on a promising pipeline. But much of that pipeline is now close to graduating towards commercial products and it's time for the company to move towards generating cash flows for investors while also finding new programs to replace... More